Natixis Advisors, L.P. Astrazeneca PLC Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Astrazeneca PLC stock. As of the latest transaction made, Natixis Advisors, L.P. holds 2,060,198 shares of AZN stock, worth $153 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
2,060,198
Previous 1,960,815
5.07%
Holding current value
$153 Million
Previous $153 Million
11.64%
% of portfolio
0.25%
Previous 0.3%
Shares
30 transactions
Others Institutions Holding AZN
# of Institutions
1,356Shares Held
512MCall Options Held
6.08MPut Options Held
4.44M-
Price T Rowe Associates Inc Baltimore, MD60.4MShares$4.48 Billion0.46% of portfolio
-
Primecap Management CO Pasadena, CA41MShares$3.04 Billion2.12% of portfolio
-
Capital International Investors Los Angeles, CA37.5MShares$2.78 Billion0.48% of portfolio
-
Wellington Management Group LLP Boston, MA37MShares$2.75 Billion0.46% of portfolio
-
Bank Of America Corp Charlotte, NC24MShares$1.78 Billion0.13% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $230B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...